Advanced iPSC Workflows: Accelerating Cell Therapy Development
Summary: Catalent’s advanced iPSC-based platforms offer GMP-ready solutions for gene editing and cell differentiation, enabling partners to streamline therapeutic development. With proprietary protocols, high-efficiency workflows, and regulatory-aligned iPSC banking, Catalent empowers scalable, high-purity manufacturing of diverse cell types including MSCs, RPEs, cardiomyocytes, and immune cells.